{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:47:28Z","timestamp":1793371648268,"version":"4.5.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001102","name":"Cancer Council NSW","doi-asserted-by":"publisher","award":["RG 23-04"],"award-info":[{"award-number":["RG 23-04"]}],"id":[{"id":"10.13039\/501100001102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001102","name":"Cancer Council NSW","doi-asserted-by":"publisher","award":["RG 25-13"],"award-info":[{"award-number":["RG 25-13"]}],"id":[{"id":"10.13039\/501100001102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001111","name":"Cancer Australia","doi-asserted-by":"publisher","award":["2020_PdCCRS_2001432"],"award-info":[{"award-number":["2020_PdCCRS_2001432"]}],"id":[{"id":"10.13039\/501100001111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001111","name":"Cancer Australia","doi-asserted-by":"publisher","award":["2023_PCRS_0269"],"award-info":[{"award-number":["2023_PCRS_0269"]}],"id":[{"id":"10.13039\/501100001111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009727","name":"Hospital Research Foundation","doi-asserted-by":"publisher","award":["2022-CP-IDMH-019"],"award-info":[{"award-number":["2022-CP-IDMH-019"]}],"id":[{"id":"10.13039\/100009727","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000950","name":"Cancer Council South Australia","doi-asserted-by":"publisher","award":["PRF2919"],"award-info":[{"award-number":["PRF2919"]}],"id":[{"id":"10.13039\/501100000950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In prostate cancer, the development of resistance to androgen receptor (AR)-targeted therapies (ATTs) and chemotherapies is associated with the emergence of new phenotypic states with altered molecular features. Here, we identify ubiquitin-specific peptidase 2 (USP2) as a mediator of this phenomenon. USP2 is induced in response to ATTs and more highly expressed in aggressive, castration-resistant prostate tumours that have lost dependence on AR as an oncogenic driver. Overexpression of USP2 in prostate cancer cells elicited elevated rates of glycolysis, neuroendocrine features and resistance to docetaxel, an important chemotherapeutic agent for advanced prostate cancer. USP2 stabilised key oncoproteins, including Aurora kinase A, cyclin D1 and fatty acid synthase. An unbiased proteomic approach identified potential new USP2 substrates and a USP2-regulated proteome that is associated with metastatic disease. Genetic or pharmacological targeting of USP2 caused cell death in human and mouse models of aggressive prostate cancer and the USP2 inhibitor ML364 exhibited potent anti-tumour effects against an orthotopic xenograft model of AR-null disease. Collectively, this study identifies USP2 as a critical regulator of proteins involved in prostate cancer progression and therapy resistance, positioning it as a viable therapeutic target.<\/jats:p>","DOI":"10.1038\/s41419-026-08923-7","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T13:58:59Z","timestamp":1780408739000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["USP2 is an androgen-repressed survival factor that stabilises oncoproteins to facilitate therapy resistance in prostate cancer"],"prefix":"10.1038","volume":"17","author":[{"given":"Danielle Meiwen","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj K.","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5105-4583","authenticated-orcid":false,"given":"Beatriz","family":"German","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5124-1352","authenticated-orcid":false,"given":"Razia","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott L.","family":"Townley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0588-8016","authenticated-orcid":false,"given":"Jianling","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne R.","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Iggo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7779-2697","authenticated-orcid":false,"given":"Zeyad D.","family":"Nassar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Helm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashikanth","family":"Marri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex D.","family":"Colella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giles","family":"Best","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret M.","family":"Centenera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne D.","family":"Tilley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim K.","family":"Chataway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2698-3220","authenticated-orcid":false,"given":"Lisa M.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4686-1418","authenticated-orcid":false,"given":"Luke A.","family":"Selth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"8923_CR1","doi-asserted-by":"publisher","first-page":"T179","DOI":"10.1530\/ERC-16-0422","volume":"23","author":"I Coutinho","year":"2016","unstructured":"Coutinho I, Day TK, Tilley WD, Selth LA. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. Endocr-Relat cancer. 2016;23:T179\u2013T197.","journal-title":"Endocr-Relat cancer"},{"key":"8923_CR2","doi-asserted-by":"crossref","unstructured":"Rollin SPG, Lawrence MG, Joshua AM, Selth LA. Friend or foe? Deciphering androgen receptor action to improve bipolar androgen therapy for prostate cancer. Endocr Relat Cancer. 2025; 32:e240208.","DOI":"10.1530\/ERC-24-0208"},{"key":"8923_CR3","doi-asserted-by":"publisher","first-page":"R35","DOI":"10.1530\/ERC-19-0420","volume":"27","author":"A Davies","year":"2020","unstructured":"Davies A, Zoubeidi A, Selth LA. The epigenetic and transcriptional landscape of neuroendocrine prostate cancer. Endocr-Relat cancer. 2020;27:R35\u2013R50.","journal-title":"Endocr-Relat cancer"},{"key":"8923_CR4","doi-asserted-by":"crossref","unstructured":"Aggarwal RR, Quigley DA, Huang J, Zhang L, Beer TM, Rettig MB, et al. Whole genome and transcriptional analysis of treatment-emergent small cell neuroendocrine prostate cancer demonstrates intra-class heterogeneity. Mol Cancer Res. 2019;17:1235\u201340.","DOI":"10.1158\/1541-7786.MCR-18-1101"},{"key":"8923_CR5","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1158\/2159-8290.CD-11-0259","volume":"1","author":"A Aparicio","year":"2011","unstructured":"Aparicio A, Logothetis CJ, Maity SN. Understanding the lethal variant of prostate cancer: the power of examining extremes. Cancer Discov. 2011;1:466\u20138.","journal-title":"Cancer Discov"},{"key":"8923_CR6","doi-asserted-by":"crossref","unstructured":"Davies AH, Beltran H, Zoubeidi A. Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Nat Rev Urol 2018;15:271\u201386.","DOI":"10.1038\/nrurol.2018.22"},{"key":"8923_CR7","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1158\/2159-8290.CD-23-0225","volume":"13","author":"A Davies","year":"2023","unstructured":"Davies A, Zoubeidi A, Beltran H, Selth LA. The transcriptional and epigenetic landscape of cancer cell lineage plasticity. Cancer Discov. 2023;13:1771\u201388.","journal-title":"Cancer Discov"},{"key":"8923_CR8","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.tcb.2013.12.003","volume":"24","author":"G Kleiger","year":"2014","unstructured":"Kleiger G, Mayor T. Perilous journey: a tour of the ubiquitin-proteasome system. Trends Cell Biol. 2014;24:352\u20139.","journal-title":"Trends Cell Biol"},{"key":"8923_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrd.2017.152","volume":"17","author":"JA Harrigan","year":"2018","unstructured":"Harrigan JA, Jacq X, Martin NM, Jackson SP. Deubiquitylating enzymes and drug discovery: emerging opportunities. Nat Rev Drug Discov. 2018;17:57\u201378.","journal-title":"Nat Rev Drug Discov"},{"key":"8923_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12929-019-0522-0","volume":"26","author":"MJ Young","year":"2019","unstructured":"Young MJ, Hsu KC, Lin TE, Chang WC, Hung JJ. The role of ubiquitin-specific peptidases in cancer progression. J Biomed Sci. 2019;26:42.","journal-title":"J Biomed Sci"},{"key":"8923_CR11","doi-asserted-by":"crossref","unstructured":"Zhang S, Guo Y, Zhang S, Wang Z, Zhang Y, Zuo S. Targeting the deubiquitinase USP2 for malignant tumor therapy (Review). Oncol Rep. 2023; 50:176.","DOI":"10.3892\/or.2023.8613"},{"key":"8923_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-15-1263","volume":"7","author":"JL Bishop","year":"2017","unstructured":"Bishop JL, Thaper D, Vahid S, Davies A, Ketola K, Kuruma H, et al. The master neural transcription factor BRN2 is an androgen receptor-suppressed driver of neuroendocrine differentiation in prostate cancer. Cancer Discov. 2017;7:54\u201371.","journal-title":"Cancer Discov"},{"key":"8923_CR13","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1158\/0008-5472.CAN-23-1489","volume":"84","author":"RK Shrestha","year":"2024","unstructured":"Shrestha RK, Nassar ZD, Hanson AR, Iggo R, Townley SL, Dehairs J, et al. ACSM1 and ACSM3 regulate fatty acid metabolism to support prostate cancer growth and constrain ferroptosis. Cancer Res. 2024;84:2313\u201332.","journal-title":"Cancer Res"},{"key":"8923_CR14","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.aah4199","volume":"355","author":"SY Ku","year":"2017","unstructured":"Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science. 2017;355:78\u201383.","journal-title":"Science"},{"key":"8923_CR15","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.1158\/0008-5472.CAN-20-3863","volume":"81","author":"LM Butler","year":"2021","unstructured":"Butler LM, Mah CY, Machiels J, Vincent AD, Irani S, Mutuku SM, et al. Lipidomic profiling of clinical prostate cancer reveals targetable alterations in membrane lipid composition. Cancer Res. 2021;81:4981\u201393.","journal-title":"Cancer Res"},{"key":"8923_CR16","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1002\/1878-0261.12354","volume":"12","author":"MM Centenera","year":"2018","unstructured":"Centenera MM, Hickey TE, Jindal S, Ryan NK, Ravindranathan P, Mohammed H, et al. A patient-derived explant (PDE) model of hormone-dependent cancer. Mol Oncol. 2018;12:1608\u201322.","journal-title":"Mol Oncol"},{"key":"8923_CR17","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8923_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.eururo.2013.08.011","volume":"66","author":"P Rajan","year":"2014","unstructured":"Rajan P, Sudbery IM, Villasevil ME, Mui E, Fleming J, Davis M, et al. Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy. Eur Urol. 2014;66:32\u201339.","journal-title":"Eur Urol"},{"key":"8923_CR19","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1432-0436.2006.00135.x","volume":"75","author":"XD Wang","year":"2007","unstructured":"Wang XD, Wang BE, Soriano R, Zha J, Zhang Z, Modrusan Z, et al. Expression profiling of the mouse prostate after castration and hormone replacement: implication of H-cadherin in prostate tumorigenesis. Differentiation. 2007;75:219\u201334.","journal-title":"Differentiation"},{"key":"8923_CR20","doi-asserted-by":"publisher","first-page":"4698","DOI":"10.1158\/1078-0432.CCR-15-0157","volume":"21","author":"X Zhang","year":"2015","unstructured":"Zhang X, Coleman IM, Brown LG, True LD, Kollath L, Lucas JM, et al. SRRM4 expression and the loss of rest activity may promote the emergence of the neuroendocrine phenotype in castration-resistant prostate cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2015;21:4698\u2013708.","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"8923_CR21","doi-asserted-by":"crossref","unstructured":"Watanabe R, Miura N, Kurata M, Kitazawa R, Kikugawa T, Saika T. Spatial gene expression analysis reveals characteristic gene expression patterns of de novo neuroendocrine prostate cancer coexisting with androgen receptor pathway prostate cancer. Int J Mol Sci 2023; 24:8955.","DOI":"10.3390\/ijms24108955"},{"key":"8923_CR22","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov"},{"key":"8923_CR23","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","volume":"163","author":"A Abeshouse","year":"2015","unstructured":"Abeshouse A, Ahn J, Akbani R, Ally A, Amin S, Andry CD, et al. The molecular taxonomy of primary prostate cancer. Cell. 2015;163:1011\u201325.","journal-title":"Cell"},{"key":"8923_CR24","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","volume":"116","author":"W Abida","year":"2019","unstructured":"Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci USA. 2019;116:11428\u201336.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8923_CR25","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ccell.2017.09.003","volume":"32","author":"EG Bluemn","year":"2017","unstructured":"Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer cell. 2017;32:474\u2013489 e476.","journal-title":"Cancer cell"},{"key":"8923_CR26","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016;22:298\u2013305.","journal-title":"Nat Med"},{"key":"8923_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25175-5","volume":"12","author":"GP Risbridger","year":"2021","unstructured":"Risbridger GP, Clark AK, Porter LH, Toivanen R, Bakshi A, Lister NL, et al. The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology. Nat Commun. 2021;12:5049.","journal-title":"Nat Commun"},{"key":"8923_CR28","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM, et al. Comprehensive integration of single-cell data. Cell. 2019;177:1888\u20131902.e1821.","journal-title":"Cell"},{"key":"8923_CR29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2509222122","volume":"122","author":"J Xie","year":"2025","unstructured":"Xie J, Shen K, Liang W, Kuang Z, Shrestha RK, Hanson AR, et al. Protein disulfide isomerases regulate androgen receptor stability and promote prostate cancer cell growth and survival. Proc Natl Acad Sci USA. 2025;122:e2509222122.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8923_CR30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15\u201321.","journal-title":"Bioinformatics"},{"key":"8923_CR31","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao Y, Smyth GK, Shi W. featureCounts: an efficient general-purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30:923\u201330.","journal-title":"Bioinformatics"},{"key":"8923_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-019-2879-1","volume":"20","author":"F Marini","year":"2019","unstructured":"Marini F, Binder H. pcaExplorer: an R\/Bioconductor package for interacting with RNA-seq principal components. BMC Bioinforma. 2019;20:331.","journal-title":"BMC Bioinforma"},{"key":"8923_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"8923_CR34","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1467-985X.2010.00676_9.x","volume":"174","author":"C Ginestet","year":"2011","unstructured":"Ginestet C. ggplot2: Elegant Graphics for Data Analysis. J R Stat Soc A. 2011;174:245\u2013245.","journal-title":"J R Stat Soc A"},{"key":"8923_CR35","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.eururo.2018.06.020","volume":"74","author":"MG Lawrence","year":"2018","unstructured":"Lawrence MG, Obinata D, Sandhu S, Selth LA, Wong SQ, Porter LH, et al. Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. Eur Urol. 2018;74:562\u201372.","journal-title":"Eur Urol"},{"key":"8923_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108585","volume":"34","author":"RC Fernandes","year":"2021","unstructured":"Fernandes RC, Toubia J, Townley S, Hanson AR, Dredge BK, Pillman KA, et al. Post-transcriptional gene regulation by microRNA-194 promotes neuroendocrine transdifferentiation in prostate cancer. Cell Rep. 2021;34:108585.","journal-title":"Cell Rep"},{"key":"8923_CR37","doi-asserted-by":"crossref","unstructured":"Gillis JL, Hinneh JA, Ryan NK, Irani S, Moldovan M, Quek LE, et al. A feedback loop between the androgen receptor and 6-phosphogluoconate dehydrogenase (6PGD) drives prostate cancer growth. eLife 2021;10 :e62592.","DOI":"10.7554\/eLife.62592"},{"key":"8923_CR38","doi-asserted-by":"crossref","unstructured":"Nassar ZD, Mah CY, Dehairs J, Burvenich IJ, Irani S, Centenera MM, et al. Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis. eLife 2020;9:e54166.","DOI":"10.7554\/eLife.54166"},{"key":"8923_CR39","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1158\/0008-5472.CAN-16-2529","volume":"77","author":"R Das","year":"2017","unstructured":"Das R, Gregory PA, Fernandes RC, Denis I, Wang Q, Townley SL, et al. MicroRNA-194 promotes prostate cancer metastasis by inhibiting SOCS2. Cancer Res. 2017;77:1021\u201334.","journal-title":"Cancer Res"},{"key":"8923_CR40","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1038\/s41416-024-02862-w","volume":"131","author":"R Rahman","year":"2024","unstructured":"Rahman R, Rahaman MH, Hanson AR, Choo N, Xie J, Townley SL, et al. Author Correction: CDK9 inhibition constrains multiple oncogenic transcriptional and epigenetic pathways in prostate cancer. Br J Cancer. 2024;131:1719.","journal-title":"Br J Cancer"},{"key":"8923_CR41","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417\u201325.","journal-title":"Cell Syst"},{"key":"8923_CR42","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nrurol.2013.126","volume":"10","author":"MM Centenera","year":"2013","unstructured":"Centenera MM, Raj GV, Knudsen KE, Tilley WD, Butler LM. Ex vivo culture of human prostate tissue and drug development. Nat Rev Urol. 2013;10:483\u20137.","journal-title":"Nat Rev Urol"},{"key":"8923_CR43","doi-asserted-by":"crossref","unstructured":"Kitamura H. Hashimoto M. USP2-related cellular signaling and consequent pathophysiological outcomes. Int J Mol Sci. 2021;22:1209.","DOI":"10.3390\/ijms22031209"},{"key":"8923_CR44","doi-asserted-by":"crossref","unstructured":"Puca L, Vlachostergios PJ, Beltran H. Neuroendocrine differentiation in prostate cancer: emerging biology, models, and therapies. Cold Spring Harb Perspect Med. 2019;9:a030593.","DOI":"10.1101\/cshperspect.a030593"},{"key":"8923_CR45","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1078-1439(97)00039-2","volume":"3","author":"R Shen","year":"1997","unstructured":"Shen R, Dorai T, Szaboles M, Katz AE, Olsson CA, Buttyan R. Transdifferentiation of cultured human prostate cancer cells to a neuroendocrine cell phenotype in a hormone-depleted medium. Urol Oncol. 1997;3:67\u201375.","journal-title":"Urol Oncol"},{"key":"8923_CR46","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","volume":"163","author":"Cancer Genome Atlas Research Network.","year":"2015","unstructured":"Cancer Genome Atlas Research Network. Electronic address scmo, cancer genome atlas research N. the molecular taxonomy of primary prostate cancer. Cell. 2015;163:1011\u201325.","journal-title":"Cell"},{"key":"8923_CR47","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/pros.23313","volume":"77","author":"HM Nguyen","year":"2017","unstructured":"Nguyen HM, Vessella RL, Morrissey C, Brown LG, Coleman IM, Higano CS, et al. LuCaP prostate cancer patient-derived xenografts reflect the molecular heterogeneity of advanced disease and serve as models for evaluating cancer therapeutics. Prostate. 2017;77:654\u201371.","journal-title":"Prostate"},{"key":"8923_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107669","volume":"31","author":"MD Nyquist","year":"2020","unstructured":"Nyquist MD, Corella A, Coleman I, De Sarkar N, Kaipainen A, Ha G, et al. Combined TP53 and RB1 loss promotes prostate cancer resistance to a spectrum of therapeutics and confers vulnerability to replication stress. Cell Rep. 2020;31:107669.","journal-title":"Cell Rep"},{"key":"8923_CR49","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41556-021-00743-5","volume":"23","author":"A Davies","year":"2021","unstructured":"Davies A, Nouruzi S, Ganguli D, Namekawa T, Thaper D, Linder S, et al. An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer. Nat Cell Biol. 2021;23:1023\u201334.","journal-title":"Nat Cell Biol"},{"key":"8923_CR50","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1093\/annonc\/mdx348","volume":"28","author":"DI Quinn","year":"2017","unstructured":"Quinn DI, Sandler HM, Horvath LG, Goldkorn A, Eastham JA. The evolution of chemotherapy for the treatment of prostate cancer. Ann Oncol. 2017;28:2658\u201369.","journal-title":"Ann Oncol"},{"key":"8923_CR51","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s41416-021-01435-5","volume":"125","author":"F Ahmad","year":"2021","unstructured":"Ahmad F, Cherukuri MK, Choyke PL. Metabolic reprogramming in prostate cancer. Br J Cancer. 2021;125:1185\u201396.","journal-title":"Br J Cancer"},{"key":"8923_CR52","doi-asserted-by":"publisher","first-page":"24628","DOI":"10.1074\/jbc.M116.738567","volume":"291","author":"MI Davis","year":"2016","unstructured":"Davis MI, Pragani R, Fox JT, Shen M, Parmar K, Gaudiano EF, et al. Small molecule inhibition of the ubiquitin-specific protease USP2 accelerates cyclin D1 degradation and leads to cell cycle arrest in colorectal cancer and mantle cell lymphoma models. J Biol Chem. 2016;291:24628\u201340.","journal-title":"J Biol Chem"},{"key":"8923_CR53","doi-asserted-by":"publisher","first-page":"38960","DOI":"10.1074\/jbc.M111.231498","volume":"286","author":"Y Shi","year":"2011","unstructured":"Shi Y, Solomon LR, Pereda-Lopez A, Giranda VL, Luo Y, Johnson EF, et al. Ubiquitin-specific cysteine protease 2a (USP2a) regulates the stability of Aurora-A. J Biol Chem. 2011;286:38960\u20138.","journal-title":"J Biol Chem"},{"key":"8923_CR54","doi-asserted-by":"publisher","first-page":"8625","DOI":"10.1158\/0008-5472.CAN-06-1374","volume":"66","author":"C Priolo","year":"2006","unstructured":"Priolo C, Tang D, Brahamandan M, Benassi B, Sicinska E, Ogino S, et al. The isopeptidase USP2a protects human prostate cancer from apoptosis. Cancer Res. 2006;66:8625\u201332.","journal-title":"Cancer Res"},{"key":"8923_CR55","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.molcel.2009.10.018","volume":"36","author":"J Shan","year":"2009","unstructured":"Shan J, Zhao W, Gu W. Suppression of cancer cell growth by promoting cyclin D1 degradation. Mol Cell. 2009;36:469\u201376.","journal-title":"Mol Cell"},{"key":"8923_CR56","doi-asserted-by":"crossref","unstructured":"Ventura E, Ducci G, Benot Dominguez R, Ruggiero V, Belfiore A, Sacco E et al. Progranulin oncogenic network in solid tumors. Cancers. 2023;15:1706.","DOI":"10.3390\/cancers15061706"},{"key":"8923_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2021.114747","volume":"193","author":"S Iliaki","year":"2021","unstructured":"Iliaki S, Beyaert R, Afonina IS. Polo-like kinase 1 (PLK1) signaling in cancer and beyond. Biochem Pharmacol. 2021;193:114747.","journal-title":"Biochem Pharmacol"},{"key":"8923_CR58","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.adi5174","volume":"18","author":"Q Zhang","year":"2025","unstructured":"Zhang Q, Peng J, Zhang Y, Liu J, He D, Zhao Y, et al. The kinase PLK1 promotes Hedgehog signaling-dependent resistance to the antiandrogen enzalutamide in metastatic prostate cancer. Sci Signal. 2025;18:eadi5174.","journal-title":"Sci Signal"},{"key":"8923_CR59","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3389\/fonc.2015.00006","volume":"5","author":"PJ Vlachostergios","year":"2015","unstructured":"Vlachostergios PJ, Papandreou CN. Targeting neuroendocrine prostate cancer: molecular and clinical perspectives. Front Oncol. 2015;5:6.","journal-title":"Front Oncol"},{"key":"8923_CR60","doi-asserted-by":"publisher","first-page":"5433","DOI":"10.1158\/1078-0432.CCR-18-1229","volume":"24","author":"D Iglesias-Gato","year":"2018","unstructured":"Iglesias-Gato D, Thysell E, Tyanova S, Crnalic S, Santos A, Lima TS, et al. The proteome of prostate cancer bone metastasis reveals heterogeneity with prognostic implications. Clin Cancer Res: Off J Am Assoc Cancer Res. 2018;24:5433\u201344.","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"8923_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00713-8","volume":"8","author":"ML Ludwig","year":"2024","unstructured":"Ludwig ML, Moline D, Horrmann A, Boytim E, Larson G, Arafa AT, et al. Integrated multi-omics assessment of lineage plasticity in a prostate cancer patient with brain and dural metastases. NPJ Precis Oncol. 2024;8:215.","journal-title":"NPJ Precis Oncol"},{"key":"8923_CR62","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.4161\/cc.11.6.19550","volume":"11","author":"J Kim","year":"2012","unstructured":"Kim J, Kim WJ, Liu Z, Loda M, Freeman MR. The ubiquitin-specific protease USP2a enhances tumor progression by targeting cyclin A1 in bladder cancer. Cell cycle. 2012;11:1123\u201330.","journal-title":"Cell cycle"},{"key":"8923_CR63","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1038\/onc.2012.188","volume":"32","author":"Z Liu","year":"2013","unstructured":"Liu Z, Zanata SM, Kim J, Peterson MA, Di Vizio D, Chirieac LR, et al. The ubiquitin-specific protease USP2a prevents endocytosis-mediated EGFR degradation. Oncogene. 2013;32:1660\u20139.","journal-title":"Oncogene"},{"key":"8923_CR64","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1038\/s41418-020-0538-8","volume":"27","author":"J Zhang","year":"2020","unstructured":"Zhang J, Liu S, Li Q, Shi Y, Wu Y, Liu F, et al. The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer. Cell Death Differ. 2020;27:2710\u201325.","journal-title":"Cell Death Differ"},{"key":"8923_CR65","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/onc.2009.330","volume":"29","author":"N Allende-Vega","year":"2010","unstructured":"Allende-Vega N, Sparks A, Lane DP, Saville MK. MdmX is a substrate for the deubiquitinating enzyme USP2a. Oncogene. 2010;29:432\u201341.","journal-title":"Oncogene"},{"key":"8923_CR66","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/sj.emboj.7601567","volume":"26","author":"LF Stevenson","year":"2007","unstructured":"Stevenson LF, Sparks A, Allende-Vega N, Xirodimas DP, Lane DP, Saville MK. The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. EMBO J. 2007;26:976\u201386.","journal-title":"EMBO J"},{"key":"8923_CR67","doi-asserted-by":"publisher","first-page":"48391","DOI":"10.18632\/oncotarget.10268","volume":"7","author":"T Wei","year":"2016","unstructured":"Wei T, Biskup E, Gjerdrum LM, Niazi O, Odum N, Gniadecki R. Ubiquitin-specific protease 2 decreases p53-dependent apoptosis in cutaneous T-cell lymphoma. Oncotarget. 2016;7:48391\u2013400.","journal-title":"Oncotarget"},{"key":"8923_CR68","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1158\/2159-8290.CD-11-0219","volume":"2","author":"B Benassi","year":"2012","unstructured":"Benassi B, Flavin R, Marchionni L, Zanata S, Pan Y, Chowdhury D, et al. MYC is activated by USP2a-mediated modulation of microRNAs in prostate cancer. Cancer Discov. 2012;2:236\u201347.","journal-title":"Cancer Discov"},{"key":"8923_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.289","volume":"4","author":"B Benassi","year":"2013","unstructured":"Benassi B, Marani M, Loda M, Blandino G. USP2a alters chemotherapeutic response by modulating redox. Cell Death Dis. 2013;4:e812.","journal-title":"Cell Death Dis"},{"key":"8923_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1512-6","volume":"10","author":"J He","year":"2019","unstructured":"He J, Lee HJ, Saha S, Ruan D, Guo H, Chan CH. Inhibition of USP2 eliminates cancer stem cells and enhances TNBC responsiveness to chemotherapy. Cell Death Dis. 2019;10:285.","journal-title":"Cell Death Dis"},{"key":"8923_CR71","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1016\/j.celrep.2018.02.007","volume":"22","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Wang X, Wang Q, Deng Y, Li K, Zhang M, et al. USP2a supports metastasis by tuning TGF-beta signaling. Cell Rep. 2018;22:2442\u201354.","journal-title":"Cell Rep"},{"key":"8923_CR72","doi-asserted-by":"publisher","first-page":"5415","DOI":"10.1007\/s13277-015-3207-7","volume":"36","author":"Q Qu","year":"2015","unstructured":"Qu Q, Mao Y, Xiao G, Fei X, Wang J, Zhang Y, et al. USP2 promotes cell migration and invasion in triple-negative breast cancer cell lines. Tumour Biol. 2015;36:5415\u201323.","journal-title":"Tumour Biol"},{"key":"8923_CR73","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/PAI.0000000000001014","volume":"30","author":"HL Ke","year":"2022","unstructured":"Ke HL, Lee YC, Li WM, Wang CS, Hsu WC, Lin HH, et al. High ubiquitin-specific protease 2a expression level predicts poor prognosis in upper tract urothelial carcinoma. Appl Immunohistochem Mol Morphol. 2022;30:304\u201310.","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"8923_CR74","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1080\/15548627.2022.2044651","volume":"18","author":"W Xiao","year":"2022","unstructured":"Xiao W, Wang J, Wang X, Cai S, Guo Y, Ye L, et al. Therapeutic targeting of the USP2-E2F4 axis inhibits autophagic machinery essential for zinc homeostasis in cancer progression. Autophagy. 2022;18:2615\u201335.","journal-title":"Autophagy"},{"key":"8923_CR75","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s13402-020-00568-8","volume":"44","author":"B Xiong","year":"2021","unstructured":"Xiong B, Huang J, Liu Y, Zou M, Zhao Z, Gong J, et al. Ubiquitin-specific protease 2a promotes hepatocellular carcinoma progression via deubiquitination and stabilization of RAB1A. Cell Oncol (Dordr). 2021;44:329\u201343.","journal-title":"Cell Oncol (Dordr)"},{"key":"8923_CR76","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.2337\/db11-0970","volume":"61","author":"MM Molusky","year":"2012","unstructured":"Molusky MM, Li S, Ma D, Yu L, Lin JD. Ubiquitin-specific protease 2 regulates hepatic gluconeogenesis and diurnal glucose metabolism through 11beta-hydroxysteroid dehydrogenase 1. Diabetes. 2012;61:1025\u201335.","journal-title":"Diabetes"},{"key":"8923_CR77","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1523\/JNEUROSCI.2504-21.2022","volume":"42","author":"M Hashimoto","year":"2022","unstructured":"Hashimoto M, Fujimoto M, Konno K, Lee ML, Yamada Y, Yamashita K, et al. Ubiquitin-specific protease 2 in the ventromedial hypothalamus modifies blood glucose levels by controlling sympathetic nervous activation. J Neurosci. 2022;42:4607\u201318.","journal-title":"J Neurosci"},{"key":"8923_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102104","volume":"49","author":"F Xu","year":"2024","unstructured":"Xu F, Xu X, Deng H, Yu Z, Huang J, Deng L, et al. The role of deubiquitinase USP2 in driving bladder cancer progression by stabilizing EZH2 to epigenetically silence SOX1 expression. Transl Oncol. 2024;49:102104.","journal-title":"Transl Oncol"},{"key":"8923_CR79","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31\u201346.","journal-title":"Cancer Discov"},{"key":"8923_CR80","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.ccell.2022.10.011","volume":"40","author":"M Han","year":"2022","unstructured":"Han M, Li F, Zhang Y, Dai P, He J, Li Y, et al. FOXA2 drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancer. Cancer cell. 2022;40:1306\u20131323.e1308.","journal-title":"Cancer cell"},{"key":"8923_CR81","doi-asserted-by":"publisher","first-page":"e53701","DOI":"10.1371\/journal.pone.0053701","volume":"8","author":"S Kregel","year":"2013","unstructured":"Kregel S, Kiriluk KJ, Rosen AM, Cai Y, Reyes EE, Otto KB, et al. Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer. PLoS ONE. 2013;8:e53701.","journal-title":"PLoS ONE"},{"key":"8923_CR82","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.aah4307","volume":"355","author":"P Mu","year":"2017","unstructured":"Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science. 2017;355:84\u201388.","journal-title":"Science"},{"key":"8923_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49234-9","volume":"15","author":"Z Wang","year":"2024","unstructured":"Wang Z, Townley SL, Zhang S, Liu M, Li M, Labaf M, et al. FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer. Nat Commun. 2024;15:4914.","journal-title":"Nat Commun"},{"key":"8923_CR84","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S1535-6108(04)00055-8","volume":"5","author":"E Graner","year":"2004","unstructured":"Graner E, Tang D, Rossi S, Baron A, Migita T, Weinstein LJ, et al. The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer cell. 2004;5:253\u201361.","journal-title":"Cancer cell"},{"key":"8923_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.101109","volume":"297","author":"F Zhang","year":"2021","unstructured":"Zhang F, Zhao Y, Sun Y. USP2 is an SKP2 deubiquitylase that stabilizes both SKP2 and its substrates. J Biol Chem. 2021;297:101109.","journal-title":"J Biol Chem"},{"key":"8923_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37617-3","volume":"14","author":"J Yi","year":"2023","unstructured":"Yi J, Tavana O, Li H, Wang D, Baer RJ, Gu W. Targeting USP2 regulation of VPRBP-mediated degradation of p53 and PD-L1 for cancer therapy. Nat Commun. 2023;14:1941.","journal-title":"Nat Commun"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08923-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08923-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08923-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T01:04:50Z","timestamp":1785978290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08923-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8923"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08923-7","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Ethical approval for the use of human prostate tumours in PDE experiments was obtained from the Human Research Ethics Committees of the University of Adelaide (Adelaide, Australia; approval #H-2012-016) and St Andrew\u2019s Hospital (Adelaide, Australia; approval #80). Animal procedures were approved by the SAHMRI Animal Ethics Committee (approval number SAM-21-042) in accordance with the guidelines of the National Health and Medical Research Council of Australia (NHMRC). PDXs were established by the Melbourne Urology Research Alliance (MURAL) (Monash University Human Research Ethics Committee approval 12287).","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"687"}}